^
No biomarker
Follicular Lymphoma
tisagenlecleucel-T
Sensitive: A1 - Approval
Novartis Press Release - Today - (New A1)
No biomarker
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive: A1 - Approval
Bristol-Myers Squibb Press Release - 1 day - (New A1)
No biomarker
Esophageal Squamous Cell Carcinoma
nivolumab + ipilimumab
Sensitive: A1 - Approval
Bristol-Myers Squibb Press Release - 1 day - (New A1)
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
pemetrexed
Sensitive: A1 - Approval
FDA - 2 days - (New A1)
No biomarker
Multiple Myeloma
ciltacabtagene autoleucel
Sensitive: A1 - Approval
J&J Press Release - 2 days - (New A1)
No biomarker
Malignant Pleural Mesothelioma
cisplatin + pemetrexed
Sensitive: A1 - Approval
FDA - 2 days - (New A1)
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
cisplatin + pemetrexed
Sensitive: A1 - Approval
FDA - 2 days - (New A1)
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
pembrolizumab
Sensitive: A1 - Approval
FDA - 2 days - (New A1)
PD-L1 expression
NSCLC
atezolizumab
Sensitive: A1 - Approval
Chugai Press Release - 2 days - (New A1)
ALK positive
NSCLC
alectinib
Sensitive: A1 - Approval
Cancer Med - 2 days - (New C3)
NTRK3 fusion
Solid Tumor
entrectinib
Sensitive: A1 - Approval
ASCO 2022 - 2 days - (New C3)
NTRK1 fusion
Solid Tumor
entrectinib
Sensitive: A1 - Approval
ASCO 2022 - 2 days - (New C3)
NTRK2 fusion
Solid Tumor
entrectinib
Sensitive: A1 - Approval
ASCO 2022 - 2 days - (New C3)
PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
nivolumab + ipilimumab
Sensitive: C1 - Off-label
ASCO 2022 - 2 days - (New C3)
HER-2 positive
HER2 Positive Breast Cancer
ARX788
Sensitive: C2 – Inclusion Criteria
Clin Cancer Res - 2 days - (New C3)
CLDN18.2 positive
Solid Tumor
MIL93
Sensitive: C2 – Inclusion Criteria
ASCO 2022 - 2 days - (New C3)
HER-2 amplification
Solid Tumor
trastuzumab + pertuzumab
Sensitive: C2 – Inclusion Criteria
ASCO 2022 - 2 days - (New C3)
PD-L1 expression
Gastric Cancer
durvalumab + AZD6738
Sensitive: C3 – Early Trials
ASCO 2022 - 2 days - (New C3)
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
tislelizumab + ZW25
Sensitive: C3 – Early Trials
ASCO 2022 - 2 days - (New C3)
HER-2 positive
Gastric Cancer
tislelizumab + ZW25
Sensitive: C3 – Early Trials
ASCO 2022 - 2 days - (New C3)
HER-2 expression
Gastroesophageal Junction Adenocarcinoma
KN026
Sensitive: C3 – Early Trials
ASCO 2022 - 2 days - (New C3)
HER-2 expression
Gastric Cancer
KN026
Sensitive: C3 – Early Trials
ASCO 2022 - 2 days - (New C3)
IDH1 mutation
AML
ivosidenib
Sensitive: A1 - Approval
Servier Press Release - 3 days - (New A1)
No biomarker
Diffuse Large B Cell Lymphoma
polatuzumab vedotin
Sensitive: A2 - Guideline
Roche Press Release - 3 days - (New B)
PD-L1 expression
Triple Negative Breast Cancer
pembrolizumab
Sensitive: A1 - Approval
NICE - 3 days - (New A2)
NRG1 fusion
Solid Tumor
MM-121
Sensitive: B - Late Trials
Elevation Oncology Press Release - 3 days - (New B)
No biomarker
Marginal Zone Lymphoma
rituximab + lenalidomide
Sensitive: A1 - Approval
FDA - 4 days - (New A1)
No biomarker
Mantle Cell Lymphoma
lenalidomide
Sensitive: A1 - Approval
FDA - 4 days - (New A1)
No biomarker
Follicular Lymphoma
rituximab + lenalidomide
Sensitive: A1 - Approval
FDA - 4 days - (New A1)
No biomarker
Triple Negative Breast Cancer
pembrolizumab
Sensitive: A1 - Approval
Merck (MSD) Press Release - 4 days - (New A1)
EGFR exon 20 insertion
NSCLC
Angiogenesis inhibitor
Sensitive: C3 – Early Trials
Cancer Med - 4 days - (New C3)
No biomarker
Pancreatic Cancer
sunitinib
Sensitive: A2 - Guideline
NCCN - 5 days - (New A2)
No biomarker
Pancreatic Cancer
temozolomide
Sensitive: A2 - Guideline
NCCN - 5 days - (New A2)
FOLR1 overexpression
Ovarian Cancer
IMGN 853
Sensitive: B - Late Trials
Immunogen Press Release - 5 days - (New B)
ALK positive
NSCLC
lorlatinib
Sensitive: A1 - Approval
J Clin Oncol - 5 days - (New B)
EGFR mutation
NSCLC
EGFR inhibitor + Angiogenesis inhibitor
Sensitive: C3 – Early Trials
BMC Cancer - 5 days - (New C3)
No biomarker
Astrocytoma
carmustine
Sensitive: A1 - Approval
FDA - 1 week - (New A1)
No biomarker
Ependymoma
carmustine
Sensitive: A1 - Approval
FDA - 1 week - (New A1)
No biomarker
Medulloblastoma
carmustine
Sensitive: A1 - Approval
FDA - 1 week - (New A1)
No biomarker
HL
carmustine
Sensitive: A1 - Approval
FDA - 1 week - (New A1)
No biomarker
NHL
carmustine
Sensitive: A1 - Approval
FDA - 1 week - (New A1)
No biomarker
Multiple Myeloma
selinexor
Sensitive: A1 - Approval
Karyopharm Press Release - 1 week - (New B)
No biomarker
Melanoma
pembrolizumab
Sensitive: A1 - Approval
Merck (MSD) Press Release - 1 week - (New B)
No biomarker
Glioma
carmustine
Sensitive: A1 - Approval
FDA - 1 week - (New A1)
No biomarker
GBM
carmustine
Sensitive: A1 - Approval
FDA - 1 week - (New A1)
No biomarker
NSCLC
sugemalimab
Sensitive: A1 - Approval
CStone Pharma Press Release - 1 week - (New B)
No biomarker
Multiple Myeloma
carmustine
Sensitive: A1 - Approval
FDA - 1 week - (New A1)
No biomarker
Juvenile Myelomonocytic Leukemia
azacitidine
Sensitive: A1 - Approval
FDA - 1 week - (New A1)
ER mutation
HER2 Negative Breast Cancer
RAD1901
Sensitive: B - Late Trials
J Clin Oncol - 1 week - (New B)
VSNL1 underexpression + CD44 underexpression
Gastric Cancer
paclitaxel
Sensitive: B - Late Trials
Sci Rep - 1 week - (New B)
BRAF V600E
Cholangiocarcinoma
vemurafenib
Sensitive: C1 - Off-label
Z Gastroenterol - 1 week - (New C4)
CD276 underexpression + EGFR mutation
LUAD
EGFR inhibitor
Sensitive: C3 – Early Trials
World J Surg Oncol - 1 week - (New C3)
EML4-ALK fusion
NSCLC
alectinib
Sensitive: C3 – Early Trials
Int J Cancer - 1 week - (New C3)
EGFR mutation + RET fusion
NSCLC
osimertinib + pralsetinib
Sensitive: C3 – Early Trials
JTO Clin Res Rep - 1 week - (New C3)
EML4-ALK fusion + TP53 mutation
NSCLC
alectinib
Resistant: C3 – Early Trials
Int J Cancer - 1 week - (New C3)
EGFR V786M
LUAD
EGFR inhibitor
Sensitive: C4 – Case Studies
Front Oncol - 1 week - (New C4)
LMO7-ALK rearrangement
LUAD
crizotinib
Sensitive: C4 – Case Studies
Front Oncol - 1 week - (New C4)
KRAS G12D
CRC
KS-58
Sensitive: D – Preclinical
Sci Rep - 1 week - (New D)
PIK3CA mutation
CRC
PI3K inhibitor
Sensitive: D – Preclinical
Med Oncol - 1 week - (New D)
PD-L1 overexpression
NSCLC
pembrolizumab
Sensitive: A2 - Guideline
Int J Clin Oncol - 2 weeks - (New C3)
IDH2 mutation
AML
venetoclax
Sensitive: A2 - Guideline
EHA 2022 - 2 weeks - (New C3)
IDH1 mutation
AML
venetoclax
Sensitive: A2 - Guideline
EHA 2022 - 2 weeks - (New C3)
Chr del(17p)
CLL
obinutuzumab + acalabrutinib
Sensitive: A2 - Guideline
EHA 2022 - 2 weeks - (New C3)
FLT3-TKD mutation
AML
gilteritinib
Sensitive: A2 - Guideline
EHA 2022 - 2 weeks - (New B)
FLT3-ITD mutation + FLT3-TKD mutation
AML
gilteritinib
Sensitive: B - Late Trials
EHA 2022 - 2 weeks - (New B)
KRAS G12C
NSCLC
Immunotherapy
Sensitive: B - Late Trials
Oncotarget - 2 weeks - (New C3)
PD-L1 overexpression
NSCLC
atezolizumab + RG6058
Sensitive: B - Late Trials
Roche Press Release - 2 weeks - (New B)
ROS1 positive
NSCLC
TPX-0005
Sensitive: B - Late Trials
Turning Point Therapeutics Press Release - 2 weeks - (New B)
Chr amplification(1)(q21)
Multiple Myeloma
lenalidomide + isatuximab-irfc
Sensitive: B - Late Trials
EHA 2022 - 2 weeks - (New B)
Chr t(14;16)
Multiple Myeloma
lenalidomide + isatuximab-irfc
Sensitive: B - Late Trials
EHA 2022 - 2 weeks - (New B)
Chr t(4;14)
Multiple Myeloma
lenalidomide + isatuximab-irfc
Sensitive: B - Late Trials
EHA 2022 - 2 weeks - (New B)
Chr del(17p)
Multiple Myeloma
lenalidomide + isatuximab-irfc
Sensitive: B - Late Trials
EHA 2022 - 2 weeks - (New B)
TMB-L
Follicular Lymphoma
rituximab
Sensitive: B - Late Trials
EHA 2022 - 2 weeks - (New B)
FLT3 mutation
AML
gilteritinib
Sensitive: A1 - Approval
EHA 2022 - 2 weeks - (New C3)
PD-L1 expression
NSCLC
durvalumab
Sensitive: A1 - Approval
Precision Oncology News - 2 weeks - (New A2)
TP53 mutation
CLL
venetoclax + obinutuzumab
Sensitive: A1 - Approval
EHA 2022 - 2 weeks - (New C3)
BCR-ABL1 T315I
CML
asciminib
Sensitive: A1 - Approval
EHA 2022 - 2 weeks - (New C3)
HR positive
HER2 Negative Breast Cancer
palbociclib
Sensitive: A1 - Approval
Clin Cancer Res - 2 weeks - (New B)
FLT3 mutation
AML
midostaurin
Sensitive: A1 - Approval
EHA 2022 - 2 weeks - (New C3)
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive: A1 - Approval
EHA 2022 - 2 weeks - (New C3)
BCR-ABL1 T315I
CML
ponatinib
Sensitive: A1 - Approval
EHA 2022 - 2 weeks - (New C3)
TP53 mutation
CLL
venetoclax
Sensitive: A1 - Approval
EHA 2022 - 2 weeks - (New C3)
Chr del(17p)
CLL
venetoclax
Sensitive: A1 - Approval
EHA 2022 - 2 weeks - (New C3)
Chr del(17p)
CLL
acalabrutinib
Sensitive: A1 - Approval
EHA 2022 - 2 weeks - (New C3)
TP53 mutation
CLL
acalabrutinib
Sensitive: A1 - Approval
EHA 2022 - 2 weeks - (New C3)
BCR-ABL1 fusion
CML
imatinib
Sensitive: A1 - Approval
EHA 2022 - 2 weeks - (New C4)
FGFR2 rearrangement
Cholangiocarcinoma
pemigatinib
Sensitive: A1 - Approval
JCO Precis Oncol - 2 weeks - (New C3)
FGFR2 fusion
Cholangiocarcinoma
pemigatinib
Sensitive: A1 - Approval
JCO Precis Oncol - 2 weeks - (New C3)
FLT3-ITD mutation
AML
gilteritinib
Sensitive: A2 - Guideline
EHA 2022 - 2 weeks - (New B)
NPM1 mutation
AML
venetoclax
Sensitive: B - Late Trials
EHA 2022 - 2 weeks - (New C3)
TP53 mutation
AML
venetoclax
Resistant: B - Late Trials
EHA 2022 - 2 weeks - (New C3)
BCR-ABL1 fusion
CML
ponatinib
Sensitive: C1 - Off-label
EHA 2022 - 2 weeks - (New C3)
PD-L1 expression
NSCLC
atezolizumab + RG6058
Sensitive: C2 – Inclusion Criteria
Lancet Oncol - 2 weeks - (New C3)
RUNX1 mutation
AML
venetoclax
Sensitive: C2 – Inclusion Criteria
EHA 2022 - 2 weeks - (New C3)
FLT3 mutation
AML
quizartinib
Sensitive: C2 – Inclusion Criteria
EHA 2022 - 2 weeks - (New C3)
IDH2 mutation
AML
MEN1703
Sensitive: C2 – Inclusion Criteria
EHA 2022 - 2 weeks - (New C3)
CLDN18.2 positive
Gastric Cancer
CT041
Sensitive: C2 – Inclusion Criteria
Nat Med - 2 weeks - (New C3)
FLT3 mutation
MDS
quizartinib
Sensitive: C2 – Inclusion Criteria
EHA 2022 - 2 weeks - (New C3)
CBL mutation
MDS
quizartinib
Sensitive: C2 – Inclusion Criteria
EHA 2022 - 2 weeks - (New C3)
U2AF1 mutation
AML
CA-4948
Sensitive: C2 – Inclusion Criteria
EHA 2022 - 2 weeks - (New C3)
SF3B1 mutation
AML
CA-4948
Sensitive: C2 – Inclusion Criteria
EHA 2022 - 2 weeks - (New C3)
SF3B1 mutation
MDS
CA-4948
Sensitive: C2 – Inclusion Criteria
EHA 2022 - 2 weeks - (New C3)
U2AF1 mutation
MDS
CA-4948
Sensitive: C2 – Inclusion Criteria
EHA 2022 - 2 weeks - (New C3)
CD79B mutation
Diffuse Large B Cell Lymphoma
zanubrutinib
Sensitive: C2 – Inclusion Criteria
EHA 2022 - 2 weeks - (New C3)
FLT3-ITD mutation
AML
HEC73543
Sensitive: C2 – Inclusion Criteria
EHA 2022 - 2 weeks - (New C3)
CRLF2 rearrangement
ALL
T-lymphocyte cell therapy + ruxolitinib
Sensitive: C2 – Inclusion Criteria
EHA 2022 - 2 weeks - (New C3)
FLT3-ITD mutation
AML
quizartinib
Sensitive: C2 – Inclusion Criteria
EHA 2022 - 2 weeks - (New C3)
IDH1 mutation
AML
cytarabine / daunorubicin liposomal formulation
Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
SF3B1 mutation
AML
venetoclax
Resistant: C3 – Early Trials
EHA 2022 - 2 weeks - (New D)
FLT3-ITD mutation
AML
venetoclax
Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
FLT3-ITD mutation
AML
venetoclax + gilteritinib
Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
ASXL1 mutation
AML
venetoclax
Resistant: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
BTK C481
CLL
LOXO-305
Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
IDH1 mutation
AML
MEN1703
Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
IGH mutation
CLL
iFCG
Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
ETV6-NTRK3 fusion
Salivary Gland Cancer
larotrectinib
Sensitive: C3 – Early Trials
The Oncologist - 2 weeks - (New C3)
BTK C481
Small Lymphocytic Lymphoma
LOXO-305
Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
CRLF2 rearrangement
ALL
T-lymphocyte cell therapy
Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
FLT3 mutation
AML
CA-4948
Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
CD20 positive
Follicular Lymphoma
obinutuzumab + INCB50465
Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
MSI-H/dMMR
CRC
PD1 inhibitor
Sensitive: C3 – Early Trials
Clin Cancer Res - 2 weeks - (New C3)
SF3B1 mutation
CLL
venetoclax
Resistant: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
miR-199a overexpression
CML
Tyrosine kinase inhibitor
Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
TNFAIP3 mutation
Marginal Zone Lymphoma
zanubrutinib
Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
MYD88 mutation
Marginal Zone Lymphoma
zanubrutinib
Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
CCND1 expression
Diffuse Large B Cell Lymphoma
R-CHOP
Resistant: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
BCL2 D103Y
CLL
venetoclax + obinutuzumab
Resistant: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
BCL2 G101V
CLL
venetoclax + rituximab
Resistant: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
BCL2 G101V
CLL
venetoclax + obinutuzumab
Resistant: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
BCL2 D103Y
CLL
venetoclax + rituximab
Resistant: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
SRSF2 mutation
AML
venetoclax
Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
CD19 positive
B Acute Lymphoblastic Leukemia
T-lymphocyte cell therapy
Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
CD20 positive
NHL
rituximab + CC-95251
Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
TP53 mutation
MDS
venetoclax + decitabine / cedazuridine
Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
TP53 mutation
CMML
venetoclax + decitabine / cedazuridine
Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
CD79B mutation
Diffuse Large B Cell Lymphoma
rituximab + zanubrutinib
Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
CD79A mutation
Diffuse Large B Cell Lymphoma
zanubrutinib
Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
CD79A mutation
Diffuse Large B Cell Lymphoma
rituximab + zanubrutinib
Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
SRSF2 mutation
MDS
venetoclax
Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
CRLF2 overexpression
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
CRLF2 overexpression
B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
CRLF2 overexpression
B Acute Lymphoblastic Leukemia
blinatumomab + inotuzumab ozogamicin
Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
SPINK2 overexpression
AML
DA
Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
BCR-ABL1 fusion + SET underexpression
CML
Tyrosine kinase inhibitor
Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
MAGEC1 expression
Multiple Myeloma
bortezomib
Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
AP2M1 overexpression
Diffuse Large B Cell Lymphoma
R-CHOP
Resistant: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
BCL2 positive + LGALS3 expression
Diffuse Large B Cell Lymphoma
R-CHOP
Resistant: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
FLT3 mutation
MDS
CA-4948
Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
CD19 positive
NHL
tisagenlecleucel-T
Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
BCL2 overexpression
HL
BEACOPP
Resistant: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
miR-16 underexpression
Multiple Myeloma
RD
Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
IGH mutation
CLL
venetoclax
Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
ALK positive
NSCLC
ALK1 inhibitor
Sensitive: C3 – Early Trials
Thorac Cancer - 2 weeks - (New C3)
CXCR3 overexpression
Urothelial Cancer
Immunotherapy
Sensitive: C3 – Early Trials
Cancer Cell Int - 2 weeks - (New C3)
CD8 overexpression
Bladder Cancer
atezolizumab
Sensitive: C3 – Early Trials
Eur Urol - 2 weeks - (New C3)
MGMT deletion
CRC
nivolumab + ipilimumab + temozolomide
Sensitive: C3 – Early Trials
J Clin Oncol - 2 weeks - (New C3)
DNMT3A mutation
MDS
RVU120
Sensitive: C4 – Case Studies
EHA 2022 - 2 weeks - (New C4)
DNMT3A mutation + NPM1 mutation
AML
RVU120
Sensitive: C4 – Case Studies
EHA 2022 - 2 weeks - (New C4)
BRAF V600E + BRAF K601_W604del
NSCLC
trametinib + dabrafenib
Sensitive: C4 – Case Studies
Cancer Genet - 2 weeks - (New C4)
KRAS G12C
NSCLC
selinexor + MRTX1257
Sensitive: D – Preclinical
Cancer Res Commun - 2 weeks - (New D)
KRAS G12C
NSCLC
sotorasib + selinexor
Sensitive: D – Preclinical
Cancer Res Commun - 2 weeks - (New D)
EGFR mutation+ IDH1 R132H
NSCLC
erlotinib + AGI-5198
Sensitive: D – Preclinical
Cancer Med - 2 weeks - (New D)
NPM1 mutation
AML
NSC23766
Sensitive: D – Preclinical
EHA 2022 - 2 weeks - (New D)
FLT3 wild-type + TP53 mutation
AML
venetoclax + gilteritinib
Sensitive: D – Preclinical
EHA 2022 - 2 weeks - (New D)
JAK2 amplification
AML
ruxolitinib
Sensitive: D – Preclinical
EHA 2022 - 2 weeks - (New D)
MYC rearrangement + BCL2 rearrangement
Lymphoma
venetoclax + DUP 785
Sensitive: D – Preclinical
EHA 2022 - 2 weeks - (New D)
EPOR amplification
AML
ruxolitinib
Sensitive: D – Preclinical
EHA 2022 - 2 weeks - (New D)
RYBP deletion
MDS
venetoclax
Sensitive: D – Preclinical
EHA 2022 - 2 weeks - (New D)
TP53 R248Q
MDS
APR-246
Sensitive: D – Preclinical
EHA 2022 - 2 weeks - (New D)
TP53 R248Q
AML
APR-246
Sensitive: D – Preclinical
EHA 2022 - 2 weeks - (New D)
MYC overexpression
Lymphoma
brusatol
Sensitive: D – Preclinical
EHA 2022 - 2 weeks - (New D)
MCT1 overexpression + SLC16A3 overexpression
Multiple Myeloma
metformin + syrosingopine
Sensitive: D – Preclinical
EHA 2022 - 2 weeks - (New D)
No biomarker
Thyroid Gland Carcinoma
cabozantinib tablet
Sensitive: A1 - Approval
Ipsen Press Release - 3 weeks - (New A1)
No biomarker
CRC
bevacizumab
Sensitive: A1 - Approval
Eur J Cancer - 3 weeks - (New B)
No biomarker
Prostate Cancer
darolutamide
Sensitive: A1 - Approval
Bayer Press Release - 3 weeks - (New B)
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + lapatinib
Sensitive: A2 - Guideline
ESMO-BC 2022 - 3 weeks - (New C3)
No biomarker
Biliary Tract Cancer
durvalumab
Sensitive: A2 - Guideline
AstraZeneca Press Release - 3 weeks - (New B)
FLT3 mutation
AML
HM43239
Sensitive: B - Late Trials
Aptose Biosci Press Release - 3 weeks - (New B)
EGFR T790M
NSCLC
osimertinib
Sensitive: A1 - Approval
ecancer - 3 weeks - (New C3)
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + tucatinib
Sensitive: A1 - Approval
Mol Cancer Ther - 3 weeks - (New D)
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + pertuzumab
Sensitive: A1 - Approval
ESMO-BC 2022 - 3 weeks - (New B)
HER-2 positive
HER2 Positive Breast Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
FDA - 3 weeks - (New A1)
HR positive
HER2 Negative Breast Cancer
ribociclib
Sensitive: A1 - Approval
ESMO-BC 2022 - 3 weeks - (New B)
HR positive
HER2 Negative Breast Cancer
abemaciclib
Sensitive: A1 - Approval
ESMO-BC 2022 - 3 weeks - (New B)
BRCA1 mutation
HER2 Negative Breast Cancer
olaparib
Sensitive: A1 - Approval
ESMO-BC 2022 - 3 weeks - (New B)
BRCA2 mutation
HER2 Negative Breast Cancer
olaparib
Sensitive: A1 - Approval
ESMO-BC 2022 - 3 weeks - (New B)
CD19 positive
B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: A1 - Approval
BeiGene Press Release - 3 weeks - (New A1)
NTRK2 fusion
Breast Cancer
entrectinib
Sensitive: A2 - Guideline
ESMO-BC 2022 - 3 weeks - (New C3)
NTRK3 fusion
Breast Cancer
entrectinib
Sensitive: A2 - Guideline
ESMO-BC 2022 - 3 weeks - (New C3)
NTRK1 fusion
Breast Cancer
entrectinib
Sensitive: A2 - Guideline
ESMO-BC 2022 - 3 weeks - (New C3)
HER-2 negative
HER2 Negative Breast Cancer
ribociclib
Sensitive: A2 - Guideline
BMC Cancer - 3 weeks - (New C3)
HER-2 negative
HER2 Negative Breast Cancer
palbociclib
Sensitive: A2 - Guideline
BMC Cancer - 3 weeks - (New C3)
HER-2 amplification
Breast Cancer
tucatinib
Sensitive: C2 – Inclusion Criteria
Mol Cancer Ther - 3 weeks - (New D)
EGFR T790M
NSCLC
bevacizumab + osimertinib
Sensitive: C2 – Inclusion Criteria
Clin Drug Investig - 3 weeks - (New C3)
HR positive
HER2 Negative Breast Cancer
eftilagimod alpha
Sensitive: C2 – Inclusion Criteria
ESMO-BC 2022 - 3 weeks - (New C3)
HER-2 positive
HER2 Positive Breast Cancer
HM 78136B
Sensitive: C2 – Inclusion Criteria
ESMO-BC 2022 - 3 weeks - (New C3)
HER-2 positive
HER2 Positive Breast Cancer
tucatinib
Sensitive: C2 – Inclusion Criteria
Mol Cancer Ther - 3 weeks - (New D)
FGFR3 mutation
Urothelial Cancer
infigratinib
Sensitive: C2 – Inclusion Criteria
J Urol - 3 weeks - (New C3)
HR positive
HER2 Negative Breast Cancer
U3-1402
Sensitive: C2 – Inclusion Criteria
ESMO-BC 2022 - 3 weeks - (New C3)
EGFR mutation
NSCLC
aumolertinib
Sensitive: C2 – Inclusion Criteria
J Exp Clin Cancer Res - 3 weeks - (New D)
BRAF wild-type
CRC
anlotinib
Sensitive: C2 – Inclusion Criteria
BMC Med - 3 weeks - (New C3)
HRD
Triple Negative Breast Cancer
cisplatin
Sensitive: C2 – Inclusion Criteria
Ther Adv Med Oncol - 3 weeks - (New C3)
ER positive
Breast Cancer
abemaciclib
Sensitive: C2 – Inclusion Criteria
Gan To Kagaku Ryoho - 3 weeks - (New C4)
PD-L1 underexpression
NSCLC
Immunotherapy
Sensitive: C3 – Early Trials
Clin Exp Immunol - 3 weeks - (New C3)
PD-L1 overexpression
NSCLC
Immunotherapy
Sensitive: C3 – Early Trials
Clin Lung Cancer - 3 weeks - (New C3)
HER-2 positive
HER2 Positive Breast Cancer
nivolumab + fam-trastuzumab deruxtecan-nxki
Sensitive: C3 – Early Trials
ESMO-BC 2022 - 3 weeks - (New C3)
KRAS mutation
Biliary Tract Cancer
anlotinib + APL-502
Resistant: C3 – Early Trials
Hepatology - 3 weeks - (New C3)
TMB-H
Biliary Tract Cancer
anlotinib + APL-502
Sensitive: C3 – Early Trials
Hepatology - 3 weeks - (New C3)
MET mutation
NSCLC
Immunotherapy
Resistant: C3 – Early Trials
Thorac Cancer - 3 weeks - (New C3)
MYC mutation
HER2 Positive Breast Cancer
trastuzumab + atezolizumab + pertuzumab
Resistant: C3 – Early Trials
ESMO-BC 2022 - 3 weeks - (New C3)
HER-2 underexpression
Breast Cancer
eribulin mesylate
Sensitive: C3 – Early Trials
ESMO-BC 2022 - 3 weeks - (New C3)
PDSS1 overexpression
HCC
Immunotherapy
Resistant: C3 – Early Trials
Cancer Manag Res - 3 weeks - (New C3)
CD8 overexpression
Breast Cancer
paclitaxel + epirubicin
Sensitive: C3 – Early Trials
ESMO-BC 2022 - 3 weeks - (New C3)
MYC amplification + HER-2 amplification
HER2 Positive Breast Cancer
trastuzumab + atezolizumab + pertuzumab
Resistant: C3 – Early Trials
ESMO-BC 2022 - 3 weeks - (New C3)
RAD21 amplification
HER2 Positive Breast Cancer
trastuzumab + atezolizumab + pertuzumab
Resistant: C3 – Early Trials
ESMO-BC 2022 - 3 weeks - (New C3)
MYC amplification
HER2 Positive Breast Cancer
trastuzumab + atezolizumab + pertuzumab
Resistant: C3 – Early Trials
ESMO-BC 2022 - 3 weeks - (New C3)
SMARCA4 deletion
NSCLC
PD-L1 inhibitor
Resistant: C3 – Early Trials
Lung Cancer - 3 weeks - (New C3)
EGFR expression
Nasopharyngeal Carcinoma
MRG003
Sensitive: C3 – Early Trials
JAMA Oncol - 3 weeks - (New C3)
EGFR expression
SCCHN
MRG003
Sensitive: C3 – Early Trials
JAMA Oncol - 3 weeks - (New C3)
EGFR T790M
LUAD
EGFR inhibitor
Sensitive: C3 – Early Trials
PLoS One - 3 weeks - (New C3)
RAS wild-type
CRC
anlotinib
Sensitive: C3 – Early Trials
BMC Med - 3 weeks - (New C3)
HER-2 778insGSP
Breast Cancer
trastuzumab + everolimus
Sensitive: C3 – Early Trials
Transl Oncol - 3 weeks - (New C3)
HER-2 S310F
Breast Cancer
trastuzumab + everolimus
Sensitive: C3 – Early Trials
Transl Oncol - 3 weeks - (New C3)
HR positive
HER2 Negative Breast Cancer
RP6530
Sensitive: C3 – Early Trials
Ann Oncol - 3 weeks - (New C3)
HRD + BRCA wild-type
Triple Negative Breast Cancer
D19466
Sensitive: C3 – Early Trials
Ther Adv Med Oncol - 3 weeks - (New C3)
HRD + BRCA wild-type
Triple Negative Breast Cancer
carboplatin
Sensitive: C3 – Early Trials
Ther Adv Med Oncol - 3 weeks - (New C3)
HRD
Triple Negative Breast Cancer
D19466
Sensitive: C3 – Early Trials
Ther Adv Med Oncol - 3 weeks - (New C3)
HRD + BRCA wild-type
Triple Negative Breast Cancer
cisplatin
Sensitive: C3 – Early Trials
Ther Adv Med Oncol - 3 weeks - (New C3)
HRD
Triple Negative Breast Cancer
carboplatin
Sensitive: C3 – Early Trials
Ther Adv Med Oncol - 3 weeks - (New C3)
TMB-H + PD-L1 expression
Soft Tissue Sarcoma
anlotinib + toripalimab
Sensitive: C4 – Case Studies
Front Immunol - 3 weeks - (New C4)
ER positive
HER2 Positive Breast Cancer
tucatinib
Sensitive: D – Preclinical
Mol Cancer Ther - 3 weeks - (New D)
TP53 mutation
Neurofibrosarcoma
AZD1775
Sensitive: D – Preclinical
Mol Cancer Ther - 3 weeks - (New D)
ADAM9 expression
Solid Tumor
IMGC936
Sensitive: D – Preclinical
Mol Cancer Ther - 3 weeks - (New D)
ERBB3 mutation
Breast Cancer
U3-1402
Sensitive: D – Preclinical
PLoS One - 3 weeks - (New D)
ALDH1A1 positive
Triple Negative Breast Cancer
EPZ-5676
Sensitive: D – Preclinical
Clin Cancer Res - 3 weeks - (New D)
MYC overexpression
NSCLC
ROS1 inhibitor
Resistant: D – Preclinical
Mol Cancer Res - 3 weeks - (New D)
HER-2 positive
Ovarian Cancer
EDIT-202
Sensitive: D – Preclinical
ASGCT 2022 - 3 weeks - (New D)
ROR1 positive
NSCLC
LYL797
Sensitive: D – Preclinical
ASGCT 2022 - 3 weeks - (New D)
ROR1 positive
Solid Tumor
LYL797
Sensitive: D – Preclinical
ASGCT 2022 - 3 weeks - (New D)
TPBG expression
AML
OXB-302
Sensitive: D – Preclinical
ASGCT 2022 - 3 weeks - (New D)
IDH1 mutation + ATRX deletion + TP53 deletion
Glioma
CAN-3110
Sensitive: D – Preclinical
ASGCT 2022 - 3 weeks - (New D)
MET amplification
CRC
cabozantinib tablet
Sensitive: D – Preclinical
J Pediatr Hematol Oncol - 3 weeks - (New D)
No biomarker
Marginal Zone Lymphoma
zanubrutinib
Sensitive: A1 - Approval
No biomarker
Multiple Myeloma
pomalidomide + elotuzumab
Sensitive: A1 - Approval
No biomarker
Diffuse Large B Cell Lymphoma
lisocabtagene maraleucel
Sensitive: A1 - Approval
CD20 positive
CLL
Truxima (rituximab biosimilar)
Sensitive: A1 - Approval
EGFR exon 19 deletion
NSCLC
afatinib
Sensitive: A1 - Approval
EGFR exon 19 deletion
NSCLC
osimertinib
Sensitive: A1 - Approval
No biomarker
NSCLC
ramucirumab
Sensitive: A1 - Approval
MSI-H/dMMR
Small Intestinal Carcinoma
pembrolizumab
Sensitive: A1 - Approval
EGFR exon 19 deletion
NSCLC
gefitinib
Sensitive: A1 - Approval
PD-L1 expression
Triple Negative Breast Cancer
atezolizumab
Sensitive: A1 - Approval
EGFR L858R
NSCLC
afatinib
Sensitive: A1 - Approval
No biomarker
NSCLC
durvalumab
Sensitive: A1 - Approval
KIT positive
GIST
imatinib
Sensitive: A1 - Approval
HER-2 positive
HER2 Positive Breast Cancer
margetuximab
Sensitive: A1 - Approval
No biomarker
RCC
nivolumab + cabozantinib tablet
Sensitive: A1 - Approval
No biomarker
Malignant Pleural Mesothelioma
nivolumab + ipilimumab
Sensitive: A1 - Approval
PD-L1 expression
NSCLC
pembrolizumab
Sensitive: A1 - Approval
ALK fusion
NSCLC
brigatinib
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab
Sensitive: A1 - Approval
No biomarker
Follicular Lymphoma
axicabtagene ciloleucel
Sensitive: A1 - Approval
No biomarker
Diffuse Large B Cell Lymphoma
axicabtagene ciloleucel
Sensitive: A1 - Approval
No biomarker
Mediastinal B Cell Lymphoma
axicabtagene ciloleucel
Sensitive: A1 - Approval
PDGFRA D842V
GIST
avapritinib
Sensitive: A1 - Approval
No biomarker
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
No biomarker
Esophageal Cancer
nivolumab
Sensitive: A1 - Approval
No biomarker
Fallopian Tube Cancer
niraparib
Sensitive: A1 - Approval
No biomarker
Ovarian Cancer
niraparib
Sensitive: A1 - Approval
No biomarker
Peritoneal Cancer
niraparib
Sensitive: A1 - Approval
No biomarker
Mantle Cell Lymphoma
brexucabtagene autoleucel
Sensitive: A1 - Approval
KRAS G12C
NSCLC
sotorasib
Sensitive: A1 - Approval
PD-L1 expression
NSCLC
nivolumab + ipilimumab
Sensitive: A1 - Approval
EGFR L858R
NSCLC
osimertinib
Sensitive: A1 - Approval
MSI-H/dMMR
Solid Tumor
dostarlimab
Sensitive: A1 - Approval
No biomarker
Esophageal Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
No biomarker
NHL
brentuximab vedotin
Sensitive: A1 - Approval
ALK positive
NSCLC
brigatinib
Sensitive: A1 - Approval
ROS1 fusion
NSCLC
entrectinib
Sensitive: A1 - Approval
No biomarker
Gastric Cancer
nivolumab
Sensitive: A1 - Approval
MET exon 14 mutation
NSCLC
tepotinib
Sensitive: A1 - Approval
No biomarker
NSCLC
bevacizumab
Sensitive: A1 - Approval
ALK positive
NHL
crizotinib
Sensitive: A1 - Approval
No biomarker
NSCLC
nivolumab + ipilimumab
Sensitive: A1 - Approval
EGFR L858R
NSCLC
dacomitinib
Sensitive: A1 - Approval
No biomarker
Small Cell Lung Cancer
durvalumab
Sensitive: A1 - Approval
EGFR T790M
NSCLC
lazertinib
Sensitive: A1 - Approval
EGFR exon 19 deletion
NSCLC
dacomitinib
Sensitive: A1 - Approval
MET exon 14 mutation
NSCLC
capmatinib
Sensitive: A1 - Approval
PD-L1 overexpression
NSCLC
cemiplimab
Sensitive: A1 - Approval
RET fusion
NSCLC
pralsetinib
Sensitive: A1 - Approval
No biomarker
SCCHN
cisplatin + 5-fluorouracil + docetaxel
Sensitive: A1 - Approval
No biomarker
Gastric Adenocarcinoma
cisplatin + 5-fluorouracil + docetaxel
Sensitive: A1 - Approval
No biomarker
Gastroesophageal Junction Adenocarcinoma
cisplatin + 5-fluorouracil + docetaxel
Sensitive: A1 - Approval
No biomarker
NSCLC
cisplatin + pemetrexed
Sensitive: A1 - Approval
No biomarker
Breast Cancer
docetaxel + doxorubicin hydrochloride + cyclophosphamide
Sensitive: A1 - Approval
No biomarker
BCC
fluorouracil topical
Sensitive: A1 - Approval
PD-L1 expression
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive: A1 - Approval
PD-L1 expression
Urothelial Cancer
atezolizumab
Sensitive: A1 - Approval
EGFR mutation
NSCLC
gefitinib
Sensitive: A1 - Approval
EGFR L858R
NSCLC
gefitinib
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
cisplatin
Sensitive: A1 - Approval
No biomarker
Multiple Myeloma
carfilzomib
Sensitive: A1 - Approval
No biomarker
Thyroid Gland Medullary Carcinoma
cabozantinib capsule
Sensitive: A1 - Approval
ALK positive
NSCLC
crizotinib
Sensitive: A1 - Approval
No biomarker
NSCLC
pembrolizumab
Sensitive: A1 - Approval
ROS1 positive
NSCLC
crizotinib
Sensitive: A1 - Approval
RET fusion
NSCLC
selpercatinib
Sensitive: A1 - Approval
EGFR mutation
NSCLC
afatinib
Sensitive: A1 - Approval
EGFR exon 20 insertion
NSCLC
mobocertinib
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
atezolizumab
Sensitive: A1 - Approval
No biomarker
Small Cell Lung Cancer
atezolizumab
Sensitive: A1 - Approval
HER-2 positive
Gastric Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
BRCA2 mutation
Pancreatic Cancer
olaparib
Sensitive: A1 - Approval
IDH2 mutation
AML
enasidenib
Sensitive: A1 - Approval
No biomarker
AML
glasdegib
Sensitive: A1 - Approval
EGFR mutation
NSCLC
erlotinib
Sensitive: A1 - Approval
PD-L1 overexpression
NSCLC
atezolizumab
Sensitive: A1 - Approval
No biomarker
HCC
pembrolizumab
Sensitive: A1 - Approval
No biomarker
HCC
bevacizumab + atezolizumab
Sensitive: A1 - Approval
No biomarker
Multiple Myeloma
bortezomib + panobinostat
Sensitive: A1 - Approval
No biomarker
Multiple Myeloma
bortezomib + pegylated liposomal doxorubicin
Sensitive: A1 - Approval
BRCA1 mutation
Pancreatic Cancer
olaparib
Sensitive: A1 - Approval
No biomarker
Diffuse Large B Cell Lymphoma
rituximab
Sensitive: A1 - Approval
HER-2 positive
HER2 Positive Breast Cancer
ado-trastuzumab emtansine
Sensitive: A1 - Approval
RET fusion
Thyroid Gland Carcinoma
pralsetinib
Sensitive: A1 - Approval
FGFR2 rearrangement
Cholangiocarcinoma
infigratinib
Sensitive: A1 - Approval
No biomarker
NSCLC
tislelizumab
Sensitive: A1 - Approval
No biomarker
Lymphoma
axicabtagene ciloleucel
Resistant: A1 - Approval
No biomarker
Diffuse Large B Cell Lymphoma
tisagenlecleucel-T
Sensitive: A1 - Approval
No biomarker
B Acute Lymphoblastic Leukemia
tisagenlecleucel-T
Sensitive: A1 - Approval
No biomarker
Childhood B Acute Lymphoblastic Leukemia
tisagenlecleucel-T
Sensitive: A1 - Approval
No biomarker
Prostate Cancer
apalutamide
Sensitive: A1 - Approval